PREVENTIVE OR TREATING AGENT FOR MYOFIBROBLAST-RELATED DISEASE

摘要

PROBLEM TO BE SOLVED: To obtain a preventive or treating agent useful for a disease caused by arterial smooth muscle cells, kidney glomerulus mesangial cells, liver stellate cells or the like which have been transformed at a focal cite by compounding an extracellular matrix having a specific function. SOLUTION: This agent contains, as an active ingredient, an extracellular matrix having a function capable of repairing a focal cite by keeping differentiation or inducing redifferentiation of myofibroblasts which have been dedifferentiated, against pericytes or smooth muscle-associated cells. A myofibroblast-related disease which is prevented or treated by the agent is preferably arterial restenosis after PTCA operation or after stent indwelling, arteriosclerosis, renal glomerulosclerosis or hepatocirrhosis. Further, the above extracellular matrix is preferably a IV-type or I-type collagen gel, and more preferably a IV-type collagen gel having the pore size of an average diameter of 5-35 nm and a polygonal network structure. The dosage is 10 mg to 10 g/body weight based on the IV-type or I-type collagen gel.